In addition to AstraZeneca, UK science advisor warns other vaccine trials likely to be paused
The U.K. government’s chief scientific advisor has said other coronavirus vaccine trials are likely to be paused in the coming months, following AstraZeneca and Oxford University’s decision to put its study on hold due to safety concerns.
“The Oxford vaccine in many ways is right at the front because it has been into more people than anyone else,” Patrick Vallance said during a press briefing. It was not an unusual step to take during late-stage trials, he continued, adding “that is precisely why Phase 3 clinical trials happen.”
Vallance said it is inevitable to some side effects and “it is sensible to look at that very seriously and understand what’s going on.”
“So, I think you should expect in some of the other trials that you will see situations where things are paused and then restarted,” Vallance said. —Sam Meredith
NIH chief says the U.S. won’t skip any vaccine safety steps
National Institutes of Health Dr. Francis Collins told a Senate committee that health officials will not skimp on safety assessments in the development of a coronavirus vaccine.
Collins said studying the safety and effectiveness of Covid-19 vaccine candidates is now the NIH’s “top priority.” An independent data and safety monitoring board is reviewing the integrity of clinical trials and continues to monitor results to ensure participants are safe, Collins told the U.S. lawmakers.
“The critical final steps in clinical trials will be well-coordinated and done in parallel with manufacturing, but with NIH and industry providing the FDA with all of the critical safety and efficacy data necessary for sound scientific decision-making,” he told the Senate Committee on Health, Education, Labor and Pensions.
The comment came a day after AstraZeneca announced that it was pausing its late-stage trial after a “suspected serious adverse reaction” in a participant in the United Kingdom. —Berkeley Lovelace Jr.
Home Depot turns Black Friday into two months of deals
An artificial Christmas tree sits on display inside a Home Depot store in New York.
Daniel Acker | Bloomberg | Getty Images
U.S. stocks opened higher as tech rebounds after massive sell-off
U.S. stocks opened higher as tech shares recovered some of the steep losses that pushed the Nasdaq Composite into correction territory, reports CNBC’s Fred Imbert and Maggie Fitzgerald.
The Dow Jones Industrial Average traded 240 points higher, or 0.8%. The S&P 500 jumped 1.3% and the Nasdaq Composite rose 1.9%. —Melodie Warner